



Zebrafish as Platform for Preclinical Compound Screening

Guest Editor:

Dr. Martin Distel

St. Anna Kinderkrebsforschung
e.V., CHILDREN'S CANCER
RESEARCH INSTITUTE,
Innovative Cancer Models,
Zimmermannplatz 10, 1090
Vienna, Austria

martin.distel@ccri.at

Deadline for manuscript
submissions:

30 November 2020

Message from the Guest Editor

Dear Colleagues,

One of the great strengths of the zebrafish model is that it is amenable to small compound screening. Numerous morphology-based screens in zebrafish have already yielded novel compounds active on developmental signaling pathways. In addition, using zebrafish models of human diseases allows for high-throughput screening to identify new therapeutic leads.

Importantly, pilot studies have shown that small compounds first discovered in zebrafish screens can be translated to humans and have led to several clinical trials.

With advances in genome-engineering technology, it is certain that many more human diseases, especially monogenetic diseases, will be modeled in zebrafish. Zebrafish is thus in a prime position among drug discovery models. In addition, automated screening and image analysis capabilities are steadily improving, and we are gaining a better understanding of pharmacokinetics and dynamics in zebrafish.

We would like to capture these exciting ongoing developments in a Special Issue of *Pharmaceuticals* and kindly ask for your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: Covered in the Science Citation Index Expanded - SCIE (Web of Science) from Vol. 10 (2017), as well as Embase and Scopus. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 3.80, which equals rank 23/164 (Q1) in 'Pharmaceutical Science' and rank 39/165 (Q1) in 'Molecular Medicine'.

Contact Us

Pharmaceuticals
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com